Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

Researchers create new platform to identify proteins for targeted treatment of disease

Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins -; a new but largely unrealized approach to the treatment of disease.

22 Mar 2024

Novel assay may improve detection and treatment of acute myeloid leukemia

A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report in The Journal of Molecular Diagnostics published by Elsevier.

13 Nov 2023

New study highlights risks of anti-ERBB2 cancer drugs during pregnancy

Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.

29 Oct 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Mast cells play a crucial role in the development of chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow.

16 May 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Protein degradation approach can be used to hit an ‘undruggable’ target against cancer

The protein STAT5 has long been an appealing target against cancer, but after decades of research it was consigned to the "undruggable" category.

15 Feb 2023

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology Annual Meeting.

13 Dec 2022

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2

21 Nov 2022

Study: Over half of the online pharmacies selling chemotherapy drugs operate unsafely or illegally

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN-; Journal of the National Comprehensive Cancer Network.

28 Jul 2022

Computer simulation model helps understand why chemotherapy resistance occurs

Understanding why and how chemotherapy resistance occurs is a major step toward optimizing treatments for cancer.

21 Jun 2022

NCCN announces the recipients of 2022 awards for oncology champions advancing cancer care

The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.

23 May 2022

CRISPR/Cas9 deletions induce adverse on-target genomic effects

Researchers utilized a CRISPR/Cas9 system to evaluate the usage of tRNA by deleting two tRNA genes from the genomes of hyper hepatocellular carcinoma and human near-haploid chronic myeloid leukemia cells.

27 Apr 2022

Cancer drugs could be repurposed as potential therapies for Alzheimer's disease

Existing and emerging cancer drugs could be repurposed as therapies to be tested in clinical trials for people at genetic risk of Alzheimer's disease, according to a new study published in Science Advances.

10 Nov 2021

Can targeting autophagy become a new approach to COVID-19 treatment?

In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.

25 Oct 2021

A new study reveals unintended CRISPR/Cas9 editing events

A recent study by researchers from Sweden and the United Kingdom shows that CRISPR/Cas9-based genomic engineering can prompt unwanted on-target effects, and highlights the complexity of human DNA repair mechanisms in the presence of the powerful prokaryotic Cas9 nuclease. The paper is currently available on the bioRxiv* preprint server.

4 Jul 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021